Company
EG 427 is a French biotechnology company that is pioneering a new approach called pinpoint gene therapy.
Our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes for use in the treatment of peripheral nervous system disorders and beyond. Our research capability is focused on ensuring our powerful platform approach has wide applicability, with potential for many products across several therapeutic areas with severe unmet medical needs.
Our first targets in the peripheral nervous system are Type C sensory neurons. Our lead asset, EG110A, targeting these neurons, is in clinical development for the treatment of neurogenic bladder dysfunction, also called NDO. EG 427 received IND clearance from the U.S. FDA for its first-in-human study with EG110A in NDO in June 2024. Our revolutionary approach to the treatment of NDO aims to provide patients with a comprehensive, long-term solution to their bladder management, through a highly selective molecular surgery approach overcoming the significant drawbacks of the current standard of care.
Philippe Chambon, MD, PhD
Founder, Chairman & CEO >
Alberto Epstein, PhD
Founder & CSO >
Cornelia Haag-Molkenteller, MD, PhD
CMO >
Samuel Salot, MSc, MBA
COO >
Don Haut, PhD
CBO >
Teddy Jégu, PhD
Head of research >
Mikael Contrastin, MSc
VP Strategy & BD >
François Giuliano, MD, PhD
Co-founder >
Pierre Denys, MD, PhD
Co-founder >
Charles Joussain, MD, PhD
Co-founder >
Heritage
Our HQ and labs are in Paris, France, where we were founded, in 2019, by a world-renowned team in the field of HSV-1 vectorology and spinal cord injury-related disorders.
Foundational research started in 2013 through a pan-European project including Universities in Versailles, France, Ferrara, Italy, and Madrid, Spain, with the goal, from the very beginning, to use the natural properties of HSV-1 as a gene therapy vector to treat neurogenic bladder disorder. This project was funded with over Euro 3 million by the European commission, the French government, SATT Paris-Saclay, and Wings for Life, a foundation dedicated to medical research on spinal cord associated diseases. EG 427 secured a worldwide exclusive license on all resulting Intellectual Property at inception of the company.
We have raised over USD 15 million, including from our Series A in 2021.
Partnerships
We believe that our uniquely flexible platform can be applied to multiple in vivo and ex vivo approaches and are looking to explore this potential through partnerships with the pharma and biotech industry.
Examples of possible indications connected to PNS: